FCFlorence Caldefie-Chézet

Florence Caldefie-Chézet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Florence Caldefie-Chézet has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Marie-Paule Vasson

    Chaire d'Excellence Program, Clermont Université, Université d'Auvergne, Unité de Nutrition Humaine, CRNH-Auvergne, INRA-UDA, Clermont-Ferrand, France; Centre Jean Perrin, Unicancer, Clermont-Ferrand, France; CHU Clermont-Ferrand, Unité d'Exploration Nutritionnelle, Clermont-Ferrand, France

    7 shared publications
  • Hermine Billard

    UMR1019-INRA-UdA, Unité de Nutrition Humaine, Equipe ECREIN, UFR Pharmacie, Université d'Auvergne, Clermont-Ferrand, France

    6 shared publications
  • Laetitia Delort

    UMR1019-INRA-UdA, Unité de Nutrition Humaine, Equipe ECREIN, UFR Pharmacie, Université d'Auvergne, Clermont-Ferrand, France

    5 shared publications
  • Adrien Rossary

    Clermont Auvergne University, INRA, UMR 1019, Human Nutrition Unit (UNH), CRNH Auvergne, Cellular Micro-Environment, Immunomodulation and Nutrition (ECREIN), Clermont-Ferrand, France

    3 shared publications
  • Virginie Dubois

    A Clermont-Université , Université d'Auvergne , Unité de Nutrition Humaine, BP10448, F-63000 Clermont-Ferrand , France and INRA, UMR 1019, UNH, ECREIN, CRNH Auvergne, Clermont-Ferrand , France

    3 shared publications
  • Delort Laetitia

    2 shared publications

Latest Publications

  • Supernatants of Adipocytes From Obese Versus Normal Weight Women and Breast Cancer Cells: In Vitro Impact on Angiogenesis

    by Lauriane Bougaret, Laetitia Delort, Hermine Billard, Charlotte Lequeux, Nicolas Goncalves‐Mendes, Ali Mojallal, Odile Damour, Marie‐Paule Vasson, Florence Caldefie‐Chezet

    Breast cancer is correlated with a higher risk of metastasis in obese postmenopausal women. Adipokines, whose plasma concentrations are modulated in obese subjects and adipocytes surround mammary cells, suggesting that adipocyte secretome affect mammary tumorogenesis. We hypothesize that mature adipocyte secretions from obese women conditioned or not by breast neoplasic cells, increase changes on the angiogenesis stages. Supernatants of human mature adipocytes, differentiated from stem cells of either adipose tissue of normal weight (MA20) or obese (MA30) women or obtained from co‐cultures between MA20 and MA30 and breast cancer cell line MCF‐7, were collected. The impact of these supernatants was investigated on proliferation, migration, and tube formation by endothelial cells (HUVEC). MA20 and MA30 showed a preservation of their “metabolic memory” (increase of Leptin, ObR, VEGF, CYP19A1, and a decrease of Adiponectin expression in MA30 compared to MA20). Supernatants from obese‐adipocytes increased HUVEC proliferation, migration, and sprouting like with supernatants obtained from co‐cultures of MA/MCF‐7 regardless the women's BMI. Additional analyses such as the use of neutralizing antibodies, analysis of supernatants (Milliplex®) and variations in gene expression (qRT‐PCR), strongly suggest an implication of IL‐6, or a synergistic action among adipokines, probably associated with that of VEGF or IL‐6. As a conclusion, supernatants from co‐cultures of MA30 and MCF‐7 cells increase proliferation, migration, and sprouting of HUVEC cells. These results provide insights into the interaction between adipocytes and epithelial cancer cells, particularly in case of obesity. The identification of synergistic action of adipokines would therefore be a great interest in developing preventive strategies. J. Cell. Physiol. 232: 1808–1816, 2017.


  • Inflammatory F2-isoprostane, prostaglandin F2α, pentraxin 3 levels and breast cancer risk: The Swedish Mammography Cohort

    by Samar Basu, Holly Harris, Alicja Wolk, Adrien Rossary, Florence Caldefie-Chézet, Marie-Paule Vasson, Anders Larsson


  • Leptin, adipocytes and breast cancer: Focus on inflammation and anti-tumor immunity

    by Laetitia Delort, Adrien Rossary, Marie-Chantal Farges, Marie-Paule Vasson, Florence Caldefie-Chézet


  • Leptin Induces a Proliferative Response in Breast Cancer Cells but Not in Normal Breast Cells

    by Virginie Dubois, Thierry Jardé, Laetitia Delort, Hermine Billard, Dominique Bernard-Gallon, Emmanuelle Berger, Alain Geloen, Marie-Paule Vasson, Florence Caldefie-Chezet

    Obesity is a risk factor for breast cancer in postmenopausal women. Leptin, a hormone excessively produced during obesity, is suggested to be involved in breast cancer. The aim of the study was to investigate procarcinogenic potential of leptin by evaluating influence of leptin on cell proliferation, cell cycle, apoptosis, and signaling on numerous breast cells lines, including 184B5 normal cells, MCF10A fibrocystic cells and MCF-7, MDA-MB-231, and T47D cancer cells. Expressions of leptin and Ob-R were analyzed using qRT-PCR and immunohistochemistry, proliferation using fluorimetric resazurin reduction test and xCELLigence system, apoptosis and cell cycle by flow cytometry, and effect of leptin on different signalling pathways using qRT-PCR and Western blot. Cells were exposed to increasing concentrations of leptin. All cell lines expressed mRNA and protein of leptin and Ob-R. Leptin stimulated proliferation of all cell lines except for 184B5 and MDA-MB-231 cells. Leptin inhibited apoptosis but didn't alter proportion of cells within cell cycle in MCF7 cells. Leptin induced overexpression of leptin, Ob-R, estrogen receptor, and aromatase mRNA in MCF-7 and T47D cells. Autoregulation induced by leptin, relationship with estrogen pathway, and proliferative and antiapoptic activity in breast cancer cells may explain that obesity-associated hyperleptinemia may be a breast cancer risk factor.


  • Leptine : implication dans la physiopathologie du cancer du sein

    by Florence Caldefie-Chézet, Virginie Dubois, Laetitia Delort, Adrien Rossary, Marie-Paule Vasson


  • Open Access

    Breast Cancer and Obesity: In Vitro Interferences between Adipokines and Proangiogenic Features and/or Antitumor Therapies?

    by Virginie Dubois, Laetitia Delort, Hermine Billard, Marie-Paule Vasson, Florence Caldefie-Chezet

    Obesity is now considered as a risk factor for breast cancer in postmenopausal women. Adipokine levels are modulated in obesity, and may play a role in carcinogenesis. Moreover, obesity increases risk of cancer mortality. Here, we hypothesized that this increase could be due to a modification in angiogenesis, capital event in the development of metastases, and/or in effectiveness of cancer treatments. To test these assumptions, following a same experimental design and simultaneously the effects of leptin and adiponectin on angiogenesis were investigated, and the impact of hyperleptinemia on anticancer drug effectiveness was measured in physiological and obesity situations. Focusing on angiogenesis, the proliferation of endothelial cells (HUVEC), which expressed leptin and adiponectin receptors, was stimulated by leptin and inhibited by adiponectin. Both adipokines globally reduced apoptosis and caspase activity. Leptin increased migration whereas adiponectin decreased migration, and leptin enhanced the area of the tubes formed by HUVEC cells while adiponectin inhibited their formation. MCF7 and MDA-MB-231 cells treated with leptin secreted more VEGF than untreated cells, whereas adiponectin treatment inhibited VEGF secretion. Finally, MCF7 cells pre-treated with leptin were more invasive than untreated cells. This effect was not reproduced in MDA-MB-231 cells. In the MCF7 breast cancer cell line, leptin could induce cell proliferation and reduced the efficacy of all breast cancer therapies (tamoxifen, 5-fluorouracil, taxol and vinblastin). These results suggest that, in obesity situation, leptin– in contrast to adiponectin – may promote tumor invasion and angiogenesis, leading to metastases ‘apparition, and reduce treatment efficacy, which could explain the increased risk of cancer mortality in cases of overweight. The evidence suggests adipokines influence breast cancer issue and could play a significant role, especially in obese patients for which hyperleptinemia, hypoadiponectinemia and increased metastatic potential are described.


  • 44: Effets des adipokines sur l’angiogenèse au cours du cancer mammaire: étude in vitro à partir de culture primaire de cellules endothéliales

    by Dubois Virginie, Laetitia Delort, Hermine Billard, Marie-Paule Vasson, Florence Caldefie-Chézet

  • 43: Influence de deux extraits de plantes alimentaires d’origine africaine sur la prolifération de cellules cancéreuses mammaires in vitro

    by Delort Laetitia, Muriel Koffi, Hermine Billard, Yao N’guessan, Marie-Paule Vasson, Pierre Chalard, Florence Caldefie-Chézet

  • 42: Glycosylations aberrantes et cancer du sein: évaluation in vitro de l’expression des antigènes Tn et T

    by Delort Laetitia, Hermine Billard, Marie-Paule Vasson, Florence Caldefie-Chézet

    • 1 February 2004
      • Vol. 91  (2) , 141-58

    [Modification of glycoconjugates during the carcinogenesis: the case of mammary carcinomas].

    by Jean Guillot, Margaret Guerry, Grazyna Konska, Florence Caldefie-Chezet, Monique De Latour, Frédérique Penault-Llorca

    Tumour growth is associated with modifications to the structure of glycan residues belonging to the glycoproteins and glycolipids present at the cell surface. These aberrant glycosylations, arising from dysfunction of glycosyltransferases and (or) glycosidases, most often result in a shortening of the glycan chains or an over-expression of structures on the cells that are normally absent or discrete. Some of these changes, such as the expression of antigen Tn in cancers of the breast or colon, appear very early in the evolution of the disease, and can indeed be found in pathologies that are generally considered benign. Most of the cell proteins are glycosylated, including the molecules involved in inter-cell recognition, attachment, cell cycle regulation and apoptosis. The consequences of these disturbances therefore affect many aspects of the biology of the cell and its fate in the body. The impact is particularly evident when the glycan moiety contributes to the functional site of the molecule, the activity of which is then modified or abolished. In addition, the expression of functional residues recognised by molecules with lectin activity, normally restricted to phagocyte cells, is liable to promote metastasis formation by favouring the crossing of the vascular endothelium by tumour cells The identification, using plant lectins and monoclonal antibodies, of oligosaccharides associated with tumour formation, is relevant for both diagnosis, as some glycotopes are expressed before any other cellular anomaly, and prognosis, since certain sequences, e.g., that recognised by L-PHA, reflect dysfunction in the glycan synthesis, culminating in the formation of terminal oside structures that favour the metastatic spread of tumour cells. Therapeutic applications can also be envisaged through action on the tumour glycan antigens by means of naturally-occurring or synthetic immunising entities, or through the use of analogues of sugars that block the activities of the glycosyltransferases or glycosidases responsible for the synthesis of potentially dangerous glycotopes. Beside their practical use, the expression of tumour glycan antigens raises the question of their role in directing the cell towards cancer formation.